Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19-Reference-Cited by-同舟云学术

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Published:2021-02-01 Issue:2 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Seftel David¹²,Boulware David R³^ORCID

Affiliation:

1. Golden Gate Fields Medical Clinic, Berkeley, California, USA

2. Enable Biosciences Inc, South San Francisco, California, USA

3. University of Minnesota Medical School, Minneapolis, Minnesota, USA

Abstract

Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab050/36152952/ofab050.pdf

Reference3 articles.

1. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: a randomized clinical trial;Lenze;JAMA,2020

2. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis;Rosen;Sci Transl Med,2019

3. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative;Franklin;Circulation,2020

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications;Scientific Reports;2024-06-12

2. Precision Medicine for COVID-19 Based on the Inflammatory Response;Infectious Diseases in Clinical Practice;2024-04-17

3. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial;eClinicalMedicine;2024-04

4. Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants;Viruses;2024-03-30

5. Effectiveness of antidepressants in improving the prognosis of COVID-19: A systematic review and meta-analysis;Atención Primaria;2024-03